InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions. (2021)
Attributed to:
Structural and cellular basis of alpha-1-antitrypsin (AT) deficiency and the serpinopathies
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.15326/jcopdf.2020.0158
PubMed Identifier: 33156982
Publication URI: http://europepmc.org/abstract/MED/33156982
Type: Journal Article/Review
Volume: 8
Parent Publication: Chronic obstructive pulmonary diseases (Miami, Fla.)
Issue: 1
ISSN: 2372-952X